Immune to Cancer: The CRI Blog
-
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…
-
Across the CEO’s Desk: February 2015 Roundup
CRI's CEO Jill O'Donnell-Tormey, PhD, shares some of the latest news in cancer immunotherapy.
-
CRI’s Impact on Colorectal Cancer Immunotherapy
CRI scientists have contributed significantly to the immunological understanding and treatment of colorectal cancer.
-
Five Myths about Clinical Trials that Just Won’t Go Away
Curious about what happens when you enroll in a clinical trial? Hear firsthand about one woman's experience.
-
Alexis and the Young Philanthropists
Since 2008, Alexis Feldman has led a group of highly motivated young New York City professionals who…
-
Knowledge is Love
Spread the word about immunotherapy this Valentine's Day.
-
Immune Checkpoint Inhibitors: What’s Next?
What’s ahead beyond CTLA-4 and PD-1?
-
World Cancer Day: The Many Languages of Cure
From Bengali to Ukrainian, our scientists have one goal: to find a cure for all cancers within…
-
What’s in a Name?
Cancer immunotherapies can have some mind-boggling names. But there’s a reason for it all.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.